Blar i forfatter "Skogen, Bjørn"

Viser treff 1-5 av 5

    • A combined effect of anti-HPA-1a and anti-HLA Class I in pregnancy? 

      Dahl, Jesper; Skogen, Bjørn; Kjær, Mette; Husebekk, Anne; Kjeldsen-Kragh, Jens; Tiller, Heidi (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-06-30)
      <i>Background</i> - Maternal anti–human leukocyte antigen (HLA) Class I is commonly detected alongside anti–human platelet antigen (HPA)-1a in fetal and neonatal alloimmune thrombocytopenia (FNAIT). Little is known regarding whether the presence of anti-HLA Class I may exert an additive effect on the risk and severity of FNAIT.<br><br> <i>Methods and Materials</i> - We reanalyzed samples originally ...

    • An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study 

      Geisen, Christof; Kjær, Mette; Fleck, Erika; Skogen, Bjørn; Armstrong, Roisin; Behrens, Frank; Bhagwagar, Zubin; Braeuninger, Susanne; Mörtberg, Anette; Olsen, Klaus Juel; Scafer, Stephan Martin Gaston; Walter, Carmen; Seifried, Erhard; Wikman, Agneta; Kjeldsen-Kragh, Jens; Koehm, Michaela (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-12-22)
      Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT cases. There are no approved therapies for FNAIT prevention or treatment. RLYB211 is a polyclonal HPA-1a hyperimmune IgG being developed to prevent ...

    • The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes 

      Ahlen, Maria Therese; Heide, Gøril; Husebekk, Anne; Skogen, Bjørn; Kjeldsen-Kragh, Jens; Stuge, Tor Brynjar (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-04-16)
      Alloimmunization against human platelet antigen (HPA)-1a during pregnancy can cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) and severe bleeding in the foetus or newborn and likely depends on several factors. HPA-1a alloimmunization is associated with <i>DRB3*01:01</i>, which is associated with several DR-DQ haplotypes. However, it is not known to what extent these haplotypes contribute ...

    • Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody 

      Mørtberg, Trude Victoria; Zhi, Huiying; Vidarsson, Gestur; Foss, Stian; Lissenberg-Thunnissen, Suzanne; Wuhrer, Manfred; Michaelsen, Terje Einar; Skogen, Bjørn; Stuge, Tor Brynjar; Andersen, Jan Terje; Newman, Peter J.; Ahlen, Maria Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-01-01)
      Maternal alloantibodies toward paternally inherited Ags on fetal platelets can cause thrombocytopenia and bleeding complications in the fetus or neonate, referred to as fetal and neonatal alloimmune thrombocytopenia (FNAIT). This is most commonly caused by Abs against the human platelet Ag (HPA)-1a in Caucasians, and a prophylactic regimen to reduce the risk for alloimmunization to women at risk ...

    • Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia 

      Kjær, Mette; Geisen, Christof; Akkøk, Cigdem Ahaein; Wikman, Agneta; Sachs, Ulrich; Bussel, James B.; Nielsen, Kaspar; Walles, Katarina; Curtis, Brian R.; Vidarsson, Gestur; Järås, Kerstin; Skogen, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-12-31)
      Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that development of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against ...